Cara Ready To Move Into Pivotal Studies In ESRD Pruritus
With a successful end-of-Phase II meeting with FDA concluded, Cara moves closer to bringing the first drug to market for pruritus in ESRD patients on dialysis.
You may also be interested in...
A Vifor Fresenius joint venture will market Korsuva for CKD-associated pruritis to Fresenius dialysis centers in Europe, and also will do a co-promotion with Cara in the US that may provide a significant head start for the drug.
The US venture Cara Therapeutics has struck the first licensing deal for its lead product candidate CR845, allying with Chong Kun Dang Pharmaceutical (CKD) for the development and marketing of the analgesic in South Korea.